Farzan Siddiqui1, Arthur K Liu1, Deborah Watkins-Bruner1, Benjamin Movsas2. 1. Farzan Siddiqui and Benjamin Movsas, Henry Ford Health System, Detroit, MI; Arthur K. Liu, University of Colorado, Aurora, CO; and Deborah Watkins-Bruner, Emory University, Atlanta, GA. 2. Farzan Siddiqui and Benjamin Movsas, Henry Ford Health System, Detroit, MI; Arthur K. Liu, University of Colorado, Aurora, CO; and Deborah Watkins-Bruner, Emory University, Atlanta, GA. bmovsas1@hfhs.org.
Abstract
PURPOSE: Although patient-reported outcomes (PROs) have become a key component of clinical oncology trials, many challenges exist regarding their optimal application. The goal of this article is to methodically review these barriers and suggest strategies to overcome them. This review will primarily focus on radiation oncology examples, will address issues regarding the "why, how, and what" of PROs, and will provide strategies for difficult problems such as methods for reducing missing data. This review will also address cancer survivorship because it closely relates to PROs. METHODS: Key articles focusing on PROs, quality of life, and survivorship issues in oncology trials are highlighted, with an emphasis on radiation oncology clinical trials. Publications and Web sites of various governmental and regulatory agencies are also reviewed. RESULTS: The study of PROs in clinical oncology trials has become well established. There are guidelines provided by organizations such as the US Food and Drug Administration that clearly indicate the importance of and methodology for studying PROs. Clinical trials in oncology have repeatedly demonstrated the value of studying PROs and suggested ways to overcome some of the key challenges. The Radiation Therapy Oncology Group (RTOG) has led some of these efforts, and their contributions are highlighted. The current state of cancer survivorship guidelines is also discussed. CONCLUSION: The study of PROs presents significant benefits in understanding and treating toxicities and enhancing quality of life; however, challenges remain. Strategies are presented to overcome these hurdles, which will ultimately improve cancer survivorship.
PURPOSE: Although patient-reported outcomes (PROs) have become a key component of clinical oncology trials, many challenges exist regarding their optimal application. The goal of this article is to methodically review these barriers and suggest strategies to overcome them. This review will primarily focus on radiation oncology examples, will address issues regarding the "why, how, and what" of PROs, and will provide strategies for difficult problems such as methods for reducing missing data. This review will also address cancer survivorship because it closely relates to PROs. METHODS: Key articles focusing on PROs, quality of life, and survivorship issues in oncology trials are highlighted, with an emphasis on radiation oncology clinical trials. Publications and Web sites of various governmental and regulatory agencies are also reviewed. RESULTS: The study of PROs in clinical oncology trials has become well established. There are guidelines provided by organizations such as the US Food and Drug Administration that clearly indicate the importance of and methodology for studying PROs. Clinical trials in oncology have repeatedly demonstrated the value of studying PROs and suggested ways to overcome some of the key challenges. The Radiation Therapy Oncology Group (RTOG) has led some of these efforts, and their contributions are highlighted. The current state of cancer survivorship guidelines is also discussed. CONCLUSION: The study of PROs presents significant benefits in understanding and treating toxicities and enhancing quality of life; however, challenges remain. Strategies are presented to overcome these hurdles, which will ultimately improve cancer survivorship.
Authors: Wilbert B van den Hout; Yvette M van der Linden; Elsbeth Steenland; Ruud G J Wiggenraad; Job Kievit; Hanneke de Haes; Jan Willem H Leer Journal: J Natl Cancer Inst Date: 2003-02-05 Impact factor: 13.506
Authors: I-Chan Huang; Tara M Brinkman; Kelly Kenzik; James G Gurney; Kirsten K Ness; Jennifer Lanctot; Elizabeth Shenkman; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: Mary S McCabe; Smita Bhatia; Kevin C Oeffinger; Gregory H Reaman; Courtney Tyne; Dana S Wollins; Melissa M Hudson Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Mirjam A G Sprangers; Jeff A Sloan; Ruut Veenhoven; Charles S Cleeland; Michele Y Halyard; Amy P Abertnethy; Frank Baas; Andrea M Barsevick; Meike Bartels; Dorret I Boomsma; Cynthia Chauhan; Amylou C Dueck; Marlene H Frost; Per Hall; Pål Klepstad; Nicholas G Martin; Christine Miaskowski; Miriam Mosing; Benjamin Movsas; Cornelis J F Van Noorden; Donald L Patrick; Nancy L Pedersen; Mary E Ropka; Quiling Shi; Gen Shinozaki; Jasvinder A Singh; Ping Yang; Ailko H Zwinderman Journal: Twin Res Hum Genet Date: 2009-06 Impact factor: 1.587
Authors: M F De Boer; B Van den Borne; J F Pruyn; R M Ryckman; L Volovics; P P Knegt; C A Meeuwis; I Mesters; C D Verwoerd Journal: Cancer Date: 1998-12-15 Impact factor: 6.860
Authors: Maria Thor; Caroline E Olsson; Jung Hun Oh; David Alsadius; Niclas Pettersson; Joseph O Deasy; Gunnar Steineck Journal: J Sex Med Date: 2015-11-13 Impact factor: 3.802
Authors: Maria Thor; Caroline Olsson; Jung Hun Oh; Stine Elleberg Petersen; David Alsadius; Lise Bentzen; Niclas Pettersson; Ludvig Paul Muren; Morten Høyer; Gunnar Steineck; Joseph O Deasy Journal: Radiother Oncol Date: 2016-02-12 Impact factor: 6.280
Authors: Amanda Caissie; Robert Olson; Lisa Barbera; Jennifer O'Donnell; Carol-Anne Davis; Jennifer Croke; Louise Bird; John Kildea; Erika Brown; Michael Brundage; Michael Milosevic Journal: Curr Oncol Date: 2022-05-19 Impact factor: 3.109
Authors: Alan L Shields; Yanni Hao; Meaghan Krohe; Andrew Yaworsky; Iyar Mazar; Catherine Foley; Faisal Mehmed; Denise Globe Journal: Am Health Drug Benefits Date: 2016-06
Authors: D Rodin; B Banihashemi; L Wang; A Lau; S Harris; W Levin; R Dinniwell; B A Millar; C Chung; N Laperriere; A Bezjak; R K S Wong Journal: Curr Oncol Date: 2016-06-09 Impact factor: 3.677
Authors: Benjamin Movsas; Chen Hu; Jeffrey Sloan; Jeffrey Bradley; Ritsuko Komaki; Gregory Masters; Vivek Kavadi; Samir Narayan; Jeff Michalski; Douglas W Johnson; Christopher Koprowski; Walter J Curran; Yolanda I Garces; Rakesh Gaur; Raymond B Wynn; John Schallenkamp; Daphna Y Gelblum; Robert M MacRae; Rebecca Paulus; Hak Choy Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777
Authors: Jeffrey A Bogart; Xiaofei Wang; Gregory A Masters; Junheng Gao; Ritsuko Komaki; Laurie E Gaspar; John V Heymach; Michael Christian Dobelbower; Charles Kuzma; Thomas E Stinchcombe; Everett E Vokes Journal: Lung Cancer Date: 2021-04-18 Impact factor: 6.081